A carregar...
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
Imatinib mesylate is a potent, molecularly targeted therapy against the oncogenic tyrosine kinase BCR-ABL. Although imatinib mesylate has considerable efficacy against chronic myeloid leukemia (CML), advanced-stage CML patients frequently become refractory to this agent. The bone marrow is the predo...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2676735/ https://ncbi.nlm.nih.gov/pubmed/18852120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-08-0314 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|